Pembrolizumab + Lenvatinib + Placebo for lenvatinib
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Urothelial Carcinoma
Conditions
Urothelial Carcinoma
Trial Timeline
May 6, 2019 → May 20, 2024
NCT ID
NCT03898180About Pembrolizumab + Lenvatinib + Placebo for lenvatinib
Pembrolizumab + Lenvatinib + Placebo for lenvatinib is a phase 3 stage product being developed by Eisai for Urothelial Carcinoma. The current trial status is completed. This product is registered under clinical trial identifier NCT03898180. Target conditions include Urothelial Carcinoma.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04889118 | Phase 3 | Completed |
| NCT04676412 | Phase 3 | Completed |
| NCT03898180 | Phase 3 | Completed |
| NCT03829332 | Phase 3 | Completed |
| NCT03820986 | Phase 3 | Completed |
Competing Products
20 competing products in Urothelial Carcinoma